文献速递白血病

儿童及青少年急性髓系白血病生存改善:荷兰发病、生存与死亡研究

Improved survival for children and young adolescents with acute myeloid leukemia: a Dutch study on incidence, survival and mortality.
PubMed 文献 · Leukemia · 2018-12-19

该研究基于荷兰癌症登记处数据,评估1990-2015年0-17岁儿童急性髓系白血病(pAML)的发病、生存与死亡趋势。5年生存率从1990年代初的40%升至2010-2015年的74%,按最新DB-AML 01方案治疗的患者死亡风险降低49%(p=0.03)。

要点

  • 1990-2015年共635例0-17岁pAML患者,年均25例(范围18-36)。
  • 5年生存率从1990年代初40%升至2010-2015年74%,几乎翻倍。
  • 按DB-AML 01方案治疗者死亡风险降低49%(p=0.03)。

核心结论

  • 荷兰pAML在1990-2015年间5年生存率显著改善,几乎从40%翻倍至74%,死亡持续下降支持真实进步。

研究设计与样本

  • 基于荷兰癌症登记处的 population-based 研究,纳入1990-2015年0-17岁pAML患者共635例,年均25例(范围18-36)。
  • 数据与荷兰儿童白血病研究组(2002年起为荷兰儿童肿瘤组DCOG)的白血病相关特征及治疗细节合并。
  • 死亡数据(1980-2016)来自荷兰统计局死因登记,进行时间趋势及按治疗方案的分析。

主要发现

  • 1990-2015年共635例0-17岁pAML患者,年均25例(范围18-36)。
  • 1-4岁发病率轻度上升,平均年度百分比变化(AAPC)为+2.2%/年(95%CI 0.8-3.5,p<0.01)。
  • 5年生存率从1990年代初的40%升至2010-2015年的74%。
  • 多变量分析显示,按最新DB-AML 01方案治疗的pAML患者死亡风险降低49%(p=0.03)。
  • 死亡率持续下降,AAPC为-2.8%/年(95%CI -4.1至-1.5)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Variation in survival of pediatric acute myeloid leukemia (pAML) over time and between Western European countries exists. The aim of the current study is to assess the progress made for the Dutch pAML population (0-17 years) during 1990-2015, based on trends in incidence, survival and mortality. Data from the population-based Netherlands Cancer Registry were merged with leukemia-related characteristics and treatment specifics from the Dutch Childhood Leukemia Study Group (Dutch Childhood Oncology Group (DCOG) from 2002 onwards). Mortality data (1980-2016) were obtained from the cause of death registry of Statistics Netherlands. Trend analyses were performed over time and by treatment protocol. Between 1990 and 2015, a total of 635 children aged 0-17 years were diagnosed with AML for an average of 25 patients (range 18-36) per year. There was a slight increase in the incidence at age 1-4 years (average annual percentage change (AAPC) of +2.2% per year (95% CI 0.8-3.5, p < 0.01)). Overall, the 5-year survival significantly improved over the past 26 years and nearly doubled from 40% in the early 1990s to 74% in 2010-2015. Multivariable analysis showed a 49% reduction in risk of death for pAML patients treated according to the latest DB-AML 01 protocol (p = 0.03). The continuing decrease of mortality (AAPC -2.8% per year (95% CI -4.1 to -1.5)) supports the conclusion of true progress against pAML in the Netherlands.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Reedijk AMJ, Klein K, Coebergh JWW, et al. Improved survival for children and young adolescents with acute myeloid leukemia: a Dutch study on incidence, survival and mortality. Leukemia. 2018. PMID: 30568171. doi:10.1038/s41375-018-0314-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。